A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment

#	Paper	IF	Citations
56	Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy. *Drugs*, **2019**, 79, 1435-1454	12.1	55
55	A patient-centric liquid chromatography-tandem mass spectrometry microsampling assay for analysis of cannabinoids in human whole blood: Application to pediatric pharmacokinetic study. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2019**, 1130-1131, 121828	3.2	3
54	Human Pharmacokinetic Parameters of Orally Administered Δ9-Tetrahydrocannabinol Capsules Are Altered by Fed Versus Fasted Conditions and Sex Differences. *Cannabis and Cannabinoid Research*, **2019**, 4, 255-264	4.6	13
53	Bench to bedside: Multiple facets of cannabinoid control in epilepsy. *Neurochemistry International*, **2020**, 141, 104898	4.4	
52	Therapeutic Applications of Cannabinoids in Cardiomyopathy and Heart Failure. *Oxidative Medicine and Cellular Longevity*, **2020**, 2020, 4587024	6.7	6
51	Plasma concentrations of eleven cannabinoids in cattle following oral administration of industrial hemp (Cannabis sativa). *Scientific Reports*, **2020**, 10, 12753	4.9	9
50	The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations. *Clinical Pharmacokinetics*, **2020**, 59, 1493-1500	6.2	9
49	Towards Better Delivery of Cannabidiol (CBD). *Pharmaceuticals*, **2020**, 13,	5.2	31
48	Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies. *Sleep Medicine Reviews*, **2020**, 53, 101339	10.2	37
47	Herbal Preparations of Medical Cannabis: A Vademecum for Prescribing Doctors. *Medicina (Lithuania)*, **2020**, 56,	3.1	29
46	A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers. *European Journal of Drug Metabolism and Pharmacokinetics*, **2020**, 45, 575-586	2.7	7
45	Cannabidiol (CBD) in Dietary Supplements: Perspectives on Science, Safety, and Potential Regulatory Approaches. *Journal of Dietary Supplements*, **2020**, 17, 493-502	2.3	11
44	Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications. *CNS Drugs*, **2020**, 34, 795-800	6.7	29
43	Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450. *Drug Metabolism and Disposition*, **2020**, 48, 1008-1017	4	19
42	Cannabinoids in the Treatment of Epilepsy: Current Status and Future Prospects. *Neuropsychiatric Disease and Treatment*, **2020**, 16, 381-396	3.1	28
41	Disposition of Oral Cannabidiol-Rich Cannabis Extracts in Children with Epilepsy. *Clinical Pharmacokinetics*, **2020**, 59, 1005-1012	6.2	4
40	Cannabidiol: pharmacology and therapeutic targets. *Psychopharmacology*, **2021**, 238, 9-28	4.7	32

#	Reference	IF	Cit
39	A validated method for the simultaneous quantification of cannabidiol, Δ-tetrahydrocannabinol, and their metabolites in human plasma and application to plasma samples from an oral cannabidiol open-label trial. *Drug Testing and Analysis*, **2021**, 13, 614-627	3.5	4
38	Comparison of Five Oral Cannabidiol Preparations in Adult Humans: Pharmacokinetics, Body Composition, and Heart Rate Variability. *Pharmaceuticals*, **2021**, 14,	5.2	7
37	Food effects on the formulation, dosing, and administration of cannabidiol (CBD) in humans: A systematic review of clinical studies. *Pharmacotherapy*, **2021**, 41, 405-420	5.8	6
36	Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies. *Pain*, **2021**, 162, S5-S25	8	17
35	Effects of Cannabidiol Supplementation on Skeletal Muscle Regeneration after Intensive Resistance Training. *Nutrients*, **2021**, 13,	6.7	8
34	Opposite Roles for Cannabidiol and Δ9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study. *Journal of Clinical Psychopharmacology*, **2021**, 41, 561-570	1.7	0
33	Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain. *Drugs*, **2021**, 81, 1513-1557	12.1	10
32	Cannabidiol and Sports Performance: a Narrative Review of Relevant Evidence and Recommendations for Future Research. *Sports Medicine - Open*, **2020**, 6, 27	6.1	20
31	Cannabidiol – decades of research and current clinical uses. *Psihiatru Ro*, **2019**, 4, 10		0
30	Routes of Administration, Pharmacokinetics and Safety of Medicinal Cannabis. **2021**, 513-557		
29	Cannabis in Palliative Medicine. **2020**, 345-372		
28	In vitro effects of cannabidiol and its main metabolites in mouse and human Sertoli cells. *Food and Chemical Toxicology*, **2021**, 159, 112722	4.7	1
27	Pain response to cannabidiol in opioid-induced hyperalgesia, acute nociceptive pain, and allodynia using a model mimicking acute pain in healthy adults in a randomized trial (CANAB II).. *Pain*, **2022**,	8	0
26	Cannabinoid-Based Medicine: Pharmacology and Drug Interactions. **2022**, 41-89		
25	Patient Evaluation: Precautions and Managing Expectations. **2022**, 153-190		
24	Pharmacokinetics, Safety, and Synovial Fluid Concentrations of Single- and Multiple-Dose Oral Administration of 1 and 3 mg/kg Cannabidiol in Horses.. *Journal of Equine Veterinary Science*, **2022**, 103933	1.2	0
23	Does Cannabidiol Have a Benefit as a Supportive Care Drug in Cancer?. *Current Treatment Options in Oncology*, **2022**, 23, 514	5.4	0
22	Enhancing Endocannabinoid Control of Stress with Cannabidiol.. *Journal of Clinical Medicine*, **2021**, 10,	5.1	1

| 21 | Cannabinoids, insomnia, and other sleep disorders.. *Chest*, **2022**, | 5.3 | 1 |

| 20 | Prediction of Carboxylesterase 1 (CES1)-mediated In Vivo Drug Interaction between Methylphenidate and Cannabinoids using Static and Physiologically Based Pharmacokinetic Models.. *Drug Metabolism and Disposition*, **2022**, | 4 | 0 |

| 19 | Effects of a Supplement Containing Cannabidiol (Cbd) on Sedation and Ataxia Scores and Health. *SSRN Electronic Journal*, | | 1 |

| 18 | Regulating for Safety: Cannabidiol Dose in Food. *Journal of Food Protection*, | 2.5 | 1 |

| 17 | Pharmacokinetics of Cannabis and Its Derivatives in Animals and Humans During Pregnancy and Breastfeeding. *Frontiers in Pharmacology*, 13, | 5.6 | |

| 16 | Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions. *Inflammopharmacology*, **2022**, 30, 1167-1178 | 5.1 | 0 |

| 15 | Effects of a Supplement Containing Cannabidiol (CBD) on Sedation and Ataxia Scores and Health. **2022**, 117, 104085 | | |

| 14 | Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration⊡ffect relations using the IB-de-risk tool. 026988112211247 | | 0 |

| 13 | Cannabidiol markedly alleviates skin and liver fibrosis. 13, | | 0 |

| 12 | The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence. | | 0 |

| 11 | Physiologically based pharmacokinetic modeling and simulation of cannabinoids in human plasma and tissues. | | 0 |

| 10 | Cannabidiol drug interaction considerations for prescribers and pharmacists. | | 0 |

| 9 | Cannabinoids and drug metabolizing enzymes: potential for drug-drug interactions and implications for drug safety and efficacy. | | 1 |

| 8 | Cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery. **2023**, 360, 114288 | | 0 |

| 7 | Cannabinoids as Prospective Anti-Cancer Drugs: Mechanism of Action in Healthy and Cancer Cells. **2022**, | | 0 |

| 6 | Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. | | 1 |

| 5 | Verifying in vitro -determined enzyme contributions to cannabidiol clearance for exposure predictions in human through physiologically based pharmacokinetic modelling. | | 0 |

| 4 | Pharmacokinetics of Cannabidiol: A systematic review and meta-regression analysis. | | 0 |

3	Pharmacovigilance on cannabidiol as an antiepileptic agent. 14,	1
2	Cannabinoids as Potential Cancer Therapeutics: The Concentration Conundrum.	0
1	Unexpected formation of dichloroacetic and trichloroacetic artefacts in gas chromatograph injector during Cannabidiol analysis. **2023**, 230, 115388	0